Central Florida's Independent Jewish Voice
(ISRAEL21c)While medical cannabis is often used to ease pain or nausea, an Israeli-American biopharmaceutical company is developing medicines containing cannabinoids—chemical compounds from cannabis plants—to treat conditions including diabetes, inflammatory diseases (like arthritis, atherosclerosis and ulcerative colitis) and cardiovascular disorders.
ISA Scientific recently signed an exclusive worldwide licensing and collaboration agreement to establish therapies containing a specific cannabinoid called cannabidiol (CBD), with Yissum, the technology-transfer company of the Hebrew University of Jerusalem, Hadasit, the technology-transfer company of the Hadassah Medical Organization in Jerusalem, and the Kennedy Trust for Rheumatology Research (KIR) in the United Kingdom.
This licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists Raphael Mechoulam and Ruth Gallily from the Hebrew University; immunologist and KIR director Sir Marc Feldman; and Hadassah physicians and researchers Chaim Lotan, Ronen Durst and Lola Weiss.
For complete article go to Israel21c.org
Reader Comments(0)